2023-504509-36-00CompletedPhase 4
Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Biocon Sdn. Bhd.
- Enrollment
- 68
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Sponsor’s Responsible Medical Monitor
Scientific
Biocon Sdn. Bhd.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy AdultsNCT07261371Pfizer64
Active, not recruiting
Not Applicable
西诺氨酯片人体生物等效性试验CTR2025430856
Active, not recruiting
Not Applicable
螺内酯片在中国健康受试者中空腹状态下随机、开放、单次给药、两制剂、两周期两序列交叉的生物等效性研究1.水肿性疾病:与其他利尿药合用,治疗充血性水肿、肝硬化腹水、肾性水肿等水肿性疾病,其目的在于纠正上述疾病时伴发的继发性醛固酮分泌增多,并对抗其他利尿药的排钾作用。也用于特发性水肿的治疗。 2.高血压:作为治疗高血压的辅助药物。 3.原发性醛固酮增多症:螺内酯可用于此病的诊断和治疗。 4.低血钾症的预防:与噻嗪类利尿药合用,增强利尿效应和预防低血钾症。CTR2025493132
Completed
Not Applicable
双氯芬酸二乙胺乳胶剂生物等效性研究CTR2025165448
Not yet recruiting
Not Applicable
Examination of equivalence between biosimilar and original in insulin lisproType 1 and type 2 diabetesJPRN-UMIN000042016Hamamatsu University School of Medicine30
